Swizzard Pharma AG hat dies direkt geteilt
Gladly sharing a summary of our H1/2024 posts on Switzerland’s market attractiveness, as well as key market access, regulatory, and quality-related topics. If you want to learn more, contact me please. Happy reading!
We’ve just wrapped up the first seven months of our series on navigating the Swiss healthcare market, where we explored the regulatory landscape, key reasons for market attractiveness, and critical quality standards. If you’re looking to expand into Switzerland, understanding the intricacies of Swissmedic and approval pathways is essential. Stay tuned for upcoming insights into marketing strategies in rare disease drugs, digital health, and personalized medicine! https://lnkd.in/d8DmChaZ #SwizzardPharma #SwissHealthcareLandscape #MarketingServices Michael Zürcher, PhD EMBA Bettina Schelbert Karin Senn